LIVINGLIVING
Medtrum
Brand: TouchCare
Pump name: A6 TouchCare System
Sensor augmented: Yes, with S6 CGM
from Medtrum.
Colour display: Yes
Careline:
Medtrum's A6 TouchCare System
incorporates a tube-free insulin patch
pump, a CGM sensor and includes a
Predictive Low Glucose Suspend (PLGS)
mechanism - a semi-closed loop system
which can help prevent hypos. Insulin
delivery is automatically suspended when
the sensor glucose is predicted to reach
the low limit in a set period of time. Basal
insulin will be automatically resumed
when the sensor glucose is within the
target range.
Relatively thin, small and light, the A6
TouchCare insulin pump has a 200-unit
insulin reservoir, infusion set, pumping
mechanism, and power supply. Basal
patterns are stored in the pump, delivery
continuing even when the PDM is out
of range. Easy to operate, with remote
bolus dosing an option, it can be worn in
the shower, when swimming and doing
other exercise. The corresponding A6
TouchCare CGM has a seven-day sensor
life and uploads data automatically to the
Medtrum software, all managed by the
TouchCare (Personal Diabetes Manager,
or PDM) connected to the sensor and
pump via Bluetooth. Using the PDM you
can see sensor information at a glance
including trend arrows with customizable
reminders and alerts.
The PDM controls the pump bas,
which is the patch part that is attached
to the body, and which comes in four
colours (pink, blue, green, lavender). The
pump base is the 'brains' of the system
and has a four-year guarantee. It does
not get thrown away after every use but
is recharged.
www.medtrum.com
continued over
Roche Diabetes Care
A survey of Accu-Chek insulin pump
users revealed that nine out of ten
people found their diabetes easier
to manage using pump therapy. The
survey, carried out by Roche Diabetes
Care, was completed by 244 people
who had been on pump therapy (AccuChek Combo or Insight) for a minimum
of one year. More than two thirds
of respondents found the following
elements of their diabetes management
had improved since switching to pump
therapy: No injections (76%); Easier
mealtime management (74%); Improved
HbA1c (70%); Gave them more stable
glucose levels (68%); Enabled discreet
management of diabetes (66%).
People were also asked how they
found the transition from pen to pump. As
many as two thirds stated that it was easy
or very easy, with almost three quarters
reporting they would have preferred an
earlier transition. The survey also sought
to identify what influences pump choice.
Respondents were asked what was
important to them when choosing a new
pump. Answers included: the ability to
use a pump discreetly, the pump using
pre-filled cartridges, the ability to integrate
a continuous glucose monitoring (CGM)
function, and having a built-in bolus
advisor.
Accu-Chek pump
user feedback